🧠 Food for thought

Implications, context, and why it matters.

Pandorum’s therapy is a “liquid cornea” designed to help address the global transplant shortage

• The company’s lead product, Kuragenx, is a “liquid cornea” applied as drops to a damaged eye. It solidifies under visible light to form a suture-less, regenerative scaffold 1.
• The method targets the global lack of donor corneas. An estimated 12 million people are waiting for a transplant 1.
• In preclinical studies, the treatment restored functional corneas in animal models 1.
• The U.S. FDA granted Orphan Drug Designation. The company expects an Investigational New Drug (IND) submission in 2025 2.

Pandorum’s manufacturing blueprint signals India’s shift to advanced biologics

• The company is rolling out a global manufacturing plan, working with AGC Biologics (Italy) for the U.S. and European markets. It also works with Nucelion Therapeutics (India) for the Asia-Pacific region 3.
• The partnership with Nucelion, a wholly owned subsidiary of Bharat Biotech, underscores India’s push to develop and make advanced biologic therapies beyond generics 4.
• The funding backs an exosome-based therapies platform. These treatments use tiny, naturally released particles cells use to communicate. Pandorum plans to expand beyond ophthalmology to address systemic inflammatory and degenerative conditions in the lung, liver, and nervous system 3.